Corbus Pharmaceuticals Holdings, Inc.

( )
CRBP PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 12.21%142.540.0%$2499.00m
BIIBBiogen, Inc. 0.00%243.771.7%$657.13m
AMGNAmgen, Inc. -0.42%223.871.3%$565.58m
GILDGilead Sciences, Inc. -0.40%59.791.0%$512.31m
BNTXBioNTech SE 2.37%112.600.0%$494.84m
VRTXVertex Pharmaceuticals, Inc. 1.15%229.311.9%$480.56m
REGNRegeneron Pharmaceuticals, Inc. 0.38%516.002.7%$475.40m
NVAXNovavax, Inc. -8.90%114.5092.9%$463.27m
ILMNIllumina, Inc. 0.00%317.033.5%$393.59m
APVOAptevo Therapeutics, Inc. -1.96%43.5218.3%$229.03m
SGENSeagen Inc. 0.00%169.125.8%$182.62m
EXASEXACT Sciences Corp. 1.02%119.4019.6%$181.30m
ALXNAlexion Pharmaceuticals, Inc. 0.95%125.002.0%$159.09m
HALOHalozyme Therapeutics, Inc. 1.17%40.7018.4%$133.20m
SRNESorrento Therapeutics, Inc. 0.61%8.201.4%$128.36m

Company Profile

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.